Diabetes Drug Cuts Cardiovascular Mortality in High-Risk Adults (FREE)
By Amy Orciari Herman Edited by André Sofair, MD, MPH Empagliflozin — a sodium glucose cotransporter 2 inhibitor approved to treat type 2 diabetes — lowers the risk for cardiovascular death among high-risk patients, according to an international, manufacturer-conducted study. The findings were presented on Thursday at the annual meeting of the European Association … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - September 18, 2015 Category: Primary Care Source Type: news
Boehringer and Lilly's diabetes drug Jardiance shows reduction in cardiovascular risk
Boehringer Ingelheim Pharmaceuticals and Eli Lilly and Company have presented the results of the EMPA-REG OUTCOME trial of Jardiance (empagliflozin) in type 2 diabetes patients at high-risk for cardiovascular (CV) events. (Source: Drug Development Technology)
Source: Drug Development Technology - September 17, 2015 Category: Pharmaceuticals Source Type: news
Lilly diabetes drug slashes deaths in patients with heart risk
(Reuters) - Eli Lilly and Co's new Jardiance pill slashed deaths by 32 percent in patients with type 2 diabetes at risk of heart attack and stroke, a finding that could make it a mainstay diabetes treatment and triple its use, according to researchers and analysts. (Source: Reuters: Health)
Source: Reuters: Health - September 17, 2015 Category: Consumer Health News Tags: healthNews Source Type: news
EMPA-REG: Unprecedented OUTCOME as Empagliflozin Cuts CV Deaths EMPA-REG: Unprecedented OUTCOME as Empagliflozin Cuts CV Deaths
For the first time ever, a type 2 diabetes drug has lowered the risk of cardiovascular death and, indeed, death from any cause, in a population of diabetics with established heart disease. Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - September 17, 2015 Category: Cardiology Tags: Diabetes & Endocrinology News Source Type: news
Jardiance Shows Cardiovascular Superiority (CME/CE)
(MedPage Today) -- First T2D drug in post-marketing trial to do so (Source: MedPage Today Nephrology)
Source: MedPage Today Nephrology - September 17, 2015 Category: Urology & Nephrology Source Type: news
